Zhangzhou Pientzehuang Pharmaceutical (600436) Stock Price, Fundamentals & Analysis

What 600436 does

Zhangzhou Pientzehuang Pharmaceutical (600436) manufactures and distributes pharmaceuticals and cosmetics in China and internationally. The company sells traditional Chinese medicines and health products in capsule, ointment, tablet, syrup, and pill forms, along with health care food, functional drinks, special efficacy cosmetics, and household chemicals under the Pien Tze Huang brand. It also operates in food sales, skin/hair/oral care daily products, biotechnology and medical device R&D, medical machinery sales, and online wholesale and retail. Its products are used for liver diseases, cardiovascular and cerebrovascular conditions, cancer, colds, dermatology, and other applications. The company exports its products and operates as a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd. It is listed on the Shanghai Stock Exchange stocks page and is part of the CSI 300 index.

Key numbers explained

• The current price is 117.4 CNY, down 2.25% today.
• The trailing P/E ratio of 39 means investors pay 39 times the company's last twelve months' earnings per share of 3.01 CNY.
• The forward P/E ratio of 24.1 uses expected future earnings, suggesting a lower valuation if those estimates hold.
• The dividend yield of 2.53% reflects the annual dividend relative to the share price, with 107% of earnings paid out as dividends.
• The beta of 0.22 indicates the stock historically moves less than the overall market.
• The debt-to-equity ratio of 6.8% shows a low level of debt compared to shareholders' equity.
• The price-to-book of 4.85 means the market values the company at nearly five times its book value.
• The 52-week range of 105.98 – 198.14 and a one-year price change of -40.7% show significant recent volatility.

What to watch

• Revenue growth is currently negative at -18.1% year over year, while the profit margin stands at 22.1% and the operating margin at 19.4%.
• The company operates in the Healthcare sector alongside peers like Guangzhou Baiyunshan Pharmaceutical Holdings (600332), Jiangsu Hengrui Medicine (600276), and Fosun Pharmaceutical (600196).
• The ex-dividend date is 31 iul. 2026, and the share count and dividend policy can affect future yield.
• Regulatory changes in drug manufacturing and broader market conditions on the Shanghai Stock Exchange can influence the stock's performance.